Publication:
Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011-2012 season in Spain, among population targeted for vaccination

dc.contributor.authorJimenez-Jorge, Silvia
dc.contributor.authorMateo-Ontañon, Salvador de
dc.contributor.authorDelgado-Sanz, Concepcion
dc.contributor.authorPozo Sanchez, Francisco
dc.contributor.authorCasas Flecha, Inmaculada
dc.contributor.authorGarcia-Cenoz, Manuel
dc.contributor.authorCastilla Catalán, Jesús
dc.contributor.authorPérez, Esteban
dc.contributor.authorGallardo, Virtudes
dc.contributor.authorRodriguez, Carolina
dc.contributor.authorVega, Tomás
dc.contributor.authorQuiñones, Carmen
dc.contributor.authorMartínez, Eva
dc.contributor.authorVanrell, Juana María
dc.contributor.authorGiménez, Jaume
dc.contributor.authorCastrillejo, Daniel
dc.contributor.authorSerrano, María del Carmen
dc.contributor.authorRamos, Julián Mauro
dc.contributor.authorLarrauri, Amparo
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderUnión Europea. European Centre for Disease Prevention and Control (ECDC)
dc.date.accessioned2019-02-04T11:15:50Z
dc.date.available2019-02-04T11:15:50Z
dc.date.issued2013-09-22
dc.description.abstractBACKGROUND: In Spain, the influenza vaccine effectiveness (VE) was estimated in the last three seasons using the observational study cycEVA conducted in the frame of the existing Spanish Influenza Sentinel Surveillance System. The objective of the study was to estimate influenza vaccine effectiveness (VE) against medically attended, laboratory-confirmed influenza-like illness (ILI) among the target groups for vaccination in Spain in the 2011-2012 season. We also studied influenza VE in the early (weeks 52/2011-7/2012) and late (weeks 8-14/2012) phases of the epidemic and according to time since vaccination. METHODS: Medically attended patients with ILI were systematically swabbed to collect information on exposure, laboratory outcome and confounding factors. Patients belonging to target groups for vaccination and who were swabbed <8 days after symptom onset were included. Cases tested positive for influenza and controls tested negative for any influenza virus. To examine the effect of a late season, analyses were performed according to the phase of the season and according to the time between vaccination and symptoms onset. RESULTS: The overall adjusted influenza VE against A(H3N2) was 45% (95% CI, 0-69). The estimated influenza VE was 52% (95% CI, -3 to 78), 40% (95% CI, -40 to 74) and 22% (95% CI, -135 to 74) at 3.5 months, 3.5-4 months, and >4 months, respectively, since vaccination. A decrease in VE with time since vaccination was only observed in individuals aged ≥ 65 years. Regarding the phase of the season, decreasing point estimates were only observed in the early phase, whereas very low or null estimates were obtained in the late phase for the shortest time interval. CONCLUSIONS: The 2011-2012 influenza vaccine showed a low-to-moderate protective effect against medically attended, laboratory-confirmed influenza in the target groups for vaccination, in a late season and with a limited match between the vaccine and circulating strains. The suggested decrease in influenza VE with time since vaccination was mostly observed in the elderly population. The decreasing protective effect of the vaccine in the late part of the season could be related to waning vaccine protection because no viral changes were identified throughout the season.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThis work was supported by the European Centre for Disease Prevention and Control (ECDC) through the I-MOVE (Influenza Monitoring Vaccine Effectiveness in Europe) project and by the Carlos III Institute of Health (Influenza A(H1N1)pdm09 Programme (GR09/0017).es_ES
dc.format.number1es_ES
dc.format.page441es_ES
dc.format.volume13es_ES
dc.identifier.citationBMC Infect Dis. 2013 Sep 22;13:441.es_ES
dc.identifier.doi10.1186/1471-2334-13-441es_ES
dc.identifier.e-issn1471-2334es_ES
dc.identifier.issn1471-2334es_ES
dc.identifier.journalBMC infectious diseaseses_ES
dc.identifier.pubmedID24053661es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/7085
dc.language.isoenges_ES
dc.publisherBioMed Central (BMC)es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/GR09/0017es_ES
dc.relation.publisherversionhttps://doi.org/10.1186/1471-2334-13-441es_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemiologíaes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshAdolescentes_ES
dc.subject.meshAgedes_ES
dc.titleEffectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011-2012 season in Spain, among population targeted for vaccinationes_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublicatione5c2a093-57c0-47ce-950f-110bc24fe8f1
relation.isAuthorOfPublicationa214b27d-fdfe-4c57-b57b-0df210b9bd10
relation.isAuthorOfPublicatione89a616b-8c7b-43b9-b3df-2a44c45e0765
relation.isAuthorOfPublication5611ffc3-de88-4908-b20a-9a15a58c060a
relation.isAuthorOfPublicatione2df6e55-f1d3-423b-a72f-fd9a69cf5915
relation.isAuthorOfPublication1cd9dae4-d8db-4946-ace0-94c29d1f775a
relation.isAuthorOfPublicatione77e1f2d-b4e2-4ba5-a853-c2795850dcae
relation.isAuthorOfPublication.latestForDiscoverye5c2a093-57c0-47ce-950f-110bc24fe8f1

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
EffectivenessOfInfluenzaVaccine_2013.pdf
Size:
920.71 KB
Format:
Adobe Portable Document Format
Description: